Cara Therapeutics, Inc.
https://www.caratherapeutics.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Cara Therapeutics, Inc.
Vifor Clinches Deal For Travere's Rare Kidney Disorder Drug
The Swiss group has delivered on its promise to secure more deals in the nephrology space by bagging the rights in Europe, Australia and New Zealand to sparsentan, which is deep into a Phase III program for focal segmental glomerulosclerosis and IgA nephropathy.
Keeping Track: US FDA Approves Korsuva, Skytrofa And Comirnaty, But Tecentriq Loses TNBC Indication
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker
Cara Gets US Approval Of I.V. Korsuva, But Prospects Murky For Oral Version
The kappa opioid receptor agonist is not listed as a scheduled substance and labeling meets expectations. Cara and partner Vifor plan to launch the product in early 2022.
Vifor Confident Of Clinching Two Deals Before Year-End
The Swiss group has posted a solid if unspectacular set of six-month results and is "working on a number of opportunities" that should close by the end of the year, according to its CFO.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
-
Biotechnology
- Large Molecule